Amarantus Bioscience Holdings, Inc., a development-stage biotechnology company, has entered into a letter of intent (LoI) with Renishaw PLC for the use of Renishaw's proprietary implantable neurosurgical products and systems, including the neuromate stereotactic robot, neuroinspire surgical planning software, and neuroinfuse - intraparenchymal delivery system for the delivery of MANF in Parkinson's disease and other neurological conditions.

Over the course of the next 12 months, the companies will collaborate to conduct certain feasibility studies to ensure the long-term viability of delivering MANF using Renishaw's product line to key brain structures. If successful, the companies expect to enter into a definitive agreement to support human clinical studies and commercial use.

Concurrently, Amarantus released the complete final report from certain neurorestoration 6-OHDA models of Parkinson's disease demonstrating MANF's ability to re-innervate the striatum following nigral injection.

Amarantus is focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis.